

10 May 2016

PureTech Health plc

Results of Annual General Meeting

The Annual General Meeting of **PureTech Health plc** ("PureTech", LSE: PRTC) plc was held at 5.00pm on Monday 9 May 2016. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.

The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.

Resolutions	For	%	Against	%	Withheld	Total votes cast
001. To receive the Company's Annual Report and Accounts for year end 31 December 2015	185,702,295	100.00	0	0.00	0	185,702,295
002. To approve the Directors' Remuneration Report	179,445,048	99.65	624,012	0.35	5,633,235	180,069,060
003. To approve the Directors' Remuneration Policy	179,963,800	99.94	105,260	0.06	5,633,235	180,069,060
004. To elect Mr. Joichi Ito as a Director	185,183,543	99.72	518,752	0.28	0	185,702,295
005. To elect Dr. Raju Kucherlapati as a Director	184,883,224	99.56	819,071	0.44	0	185,702,295
006. To elect Dr. John LaMattina as a director	185,702,295	100.00	0	0.00	0	185,702,295
007. To elect Dame Marjorie Scardino as a director	185,624,655	99.96	77,640	0.04	0	185,702,295
008. To elect Mr. Christopher Viehbach as a director	185,624,655	99.96	77,640	0.04	0	185,702,295
009. To elect Dr. Robert Langer as a director	184,920,864	99.58	781,431	0.42	0	185,702,295
010. To elect Dr. Bennett Shapiro as a director	184,960,864	99.60	741,431	0.40	0	185,702,295
011. To elect Ms. Daphne Zohar as a director	185,694,032	99.99	8,263	0.01	0	185,702,295
012. To elect Mr. Stephen Muniz as a director	185,175,280	99.72	527,015	0.28	0	185,702,295

013. To reappoint KPMG LLP as Auditors of the Company	185,352,712	99.81	349,583	0.19	0	185,702,295
014. To authorize the Board of Directors to determine the Auditor's remuneration	185,352,712	99.81	349,583	0.19	0	185,702,295
015. To authorize the allotment of shares	175,240,183	94.37	10,462,112	5.63	0	185,702,295
016. To dis-apply pre-emption rights	179,246,480	96.97	5,592,091	3.03	863,724	184,838,571
017. To authorize market purchase of own shares	185,702,295	100.00	0	0.00	0	185,702,295
018. To authorize general meetings to be called on not less than 14 clear days' notice	184,493,872	99.35	1,208,423	0.65	0	185,702,295

VOTES OF SHAREHOLDERS EXCLUDING CONTROLLING SHAREHOLDER

As the Company has a controlling shareholder, Invesco Asset Management Limited, as defined in the Financial Conduct Authority's Listing Rules, each resolution to elect an independent director (resolutions 5,6,7 and 8) have under Listing Rule 9.2.2E been approved by a majority of the votes cast by:

- the shareholders of the Company as a whole; and
- the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution excluding the controlling shareholder as shown below.

Resolutions	For	%	Against	%	Withheld	Total votes cast
005. To elect Dr. Raju Kucheralapati as a Director	108,843,564	99.25	819,071	0.75	0	109,662,635
006. To elect Dr. John LaMattina as a director	109,662,635	100.00	0	0.00	0	109,662,635
007. To elect Dame Marjorie Scardino as a director	109,584,995	99.93	77,640	0.07	0	109,662,635
008. To elect Mr. Christopher Viehbacher as a director	109,584,995	99.93	77,640	0.07	0	109,662,635

Notes:

1. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
2. As at 9 May 2016, the number of issued shares in the Company was 237,387,951 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company's website www.puretechhealth.com and on the National Storage Mechanism.

In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary healthcare company developing innovative products that could improve the lives of billions of patients. PureTech is focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastro-intestinal and immune systems, and the interactions and signalling between them. PureTech has a pipeline of more than 30 programmes and has approximately 20 clinical studies across its pipeline, targeting multi-billion dollar market opportunities. PureTech's advanced programmes include five with human proof-of-concept and multiple with pivotal or registration study readouts in the next two years. PureTech's leading team and board, along with an advisory network of more than 60 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. With healthcare undergoing major transformation, PureTech believes it is well positioned to develop and launch medicines for the 21st century. For more information, visit <http://www.puretechhealth.com> and connect with us on [Twitter](#).

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Enquiries

PureTech

Allison Mead, Associate Director, Communications and Investor Relations

+1 617 651 3156

FTI Consulting (Communications adviser to PureTech)

Ben Atwell

Matthew Cole

+44 (0) 20 3727 1000